CHICAGO, Dec. 16, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include GlaxoSmithKline (NYSE: GSK), Roche (OTC: RHHBY), Nabors Industries Ltd. (NYSE: NBR), Patterson-UTI Energy (Nasdaq: PTEN) and Ensco plc (NYSE: ESV).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday's Analyst Blog:
Pipeline Setback for Glaxo
GlaxoSmithKline (NYSE: GSK) recently announced disappointing results from a phase III study TEACH (Tykerb Evaluation After Chemotherapy) of Tykerb (lapatinib) as a delayed adjuvant monotherapy for patients suffering from HER2 positive breast cancer. The data was presented at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium.
The randomised, double-blind, placebo-controlled, study evaluated Tykerb in HER2 positive breast cancer patients, who remained disease free after receiving treatment and were not treated with Roche's (OTC: RHHBY) Herceptin (trastuzumab) in the first place. Results from the study revealed that only 13% patients in the Tykerb arm achieved disease free survival (the primary end-point) as opposed to 17% in the placebo arm after a median follow-up of 4 years.
Tykerb is approved for both as a monotherapy and also in combination with Roche's Xeloda (capecitabine) for treating patients suffering from advanced or metastatic HER2 positive breast cancer. We note that Tykerb is being evaluated for treating other oncological indications also.
Glaxo in a Neutral Lane
We currently have a Neutral recommendation on Glaxo. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
While several products in the Pharmaceuticals segment are facing generic competition, the consumer side of the business is performing well and should drive top-line growth. Moreover, Glaxo's diversified base and presence in different geographical areas should help support revenue growth. Meanwhile, Glaxo's restructuring initiative should help offset the impact of increasing generic competition in the next few years and help earnings grow faster than revenues. Share buybacks should also drive bottom-line growth. While we remain concerned about generic competition, we are pleased with the Glaxo's efforts to develop its pipeline.
Nabors Sheds California Assets
Ramshorn Investments Inc, the wholly owned subsidiary of Nabors Industries Ltd. (NYSE: NBR), announced that it has completed the divesture of all of its interests in some oil and gas properties in California. The deal will fetch Nabors approximately $72 million in cash.
The assets were sold to an undisclosed buyer in a deal that entails the purchaser to continue utilizing Nabors' rigs.
We believe this sale highlights Nabors' efforts to divest low profit generating upstream properties and re-design its asset base. Management is expected to divest other holdings throughout 2012.
Barbados-based Nabors is a leading land-drilling contractor with oil, gas, and geothermal land drilling operations across the world. The company is also one of the largest land well servicing companies and workover contractors in the U.S.
Currently, Nabors owns and operates approximately 491 land drilling rigs and 749 land workover and well-servicing rigs in North America. Nabors' actively marketed offshore fleet comprises 39 platform rigs, 12 jackup units and 4 barge rigs in the United States and multiple international markets.
We believe that Nabors enjoys a large, high-quality fleet of drilling and workover rigs. Over the years, the company has not only grown through cash flow reinvestments but has also extended its geographic reach and diversified its operating assets beyond land rigs.
We expect Nabors to present robust results in the final quarter of 2011, fueled by the addition of new and advanced rigs, better pricing and commencement of several pending projects. Management also expects attractive expansion opportunities and growing demand for oil to boost the company's performance.
However, with businesses across the globe, Nabors' operations remain susceptible to various risks such as war, civil disturbances and government actions. With natural gas fundamentals remaining weak and a high debt level, we do not see much upside potential for the company in the coming months. Thus, we are maintaining our long-term Neutral recommendation on the stock.
Nabors competes with peers such as Patterson-UTI Energy (Nasdaq: PTEN) and Ensco plc (NYSE: ESV), and currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
